Pharmaron (300759) Report Interpretation

Overview

This earnings update argues that Pharmaron’s growth is becoming more structural as CDMO orders, backlog conversion and complex-molecule exposure accelerate. HSBC maintains Buy on both A- and H-shares, lifts earnings estimates and raises target prices using an unchanged DCF framework.

Core views

Pharmaron reported a stronger-than-expected 1H26. In 2Q26, revenue grew 20.2% year-on-year and adjusted net profit rose 23.8%. Management increased FY26 revenue-growth guidance to 15-20% from 12-18%, supported by stronger orders and continued progress in the small-molecule CDMO pipeline. HSBC consequently raises its 2026-28 net-profit estimates by 6-8%, citing better backlog conversion and a faster CDMO ramp-up. Its revenue forecasts are above consensus by 3%, 7% and 10% for 2026-28, while adjusted net-profit estimates are broadly in line for 2026-27 and 4% below consensus for 2028 because it remains more conservative on lab-service and clinical-service margin expansion. CDMO is presented as the clearest earnings catalyst. CDMO revenue increased 42% year-on-year in 2Q26 and gross margin expanded 2.7 percentage points quarter-on-quarter to 26.8%. HSBC attributes this to small-molecule capacity ramp-up, migration of projects into later stages and a larger contribution from complex modalities, including molecular glues, oral small molecules and peptides, PROTACs and ADCs. Pharmaron reported 782 small-molecule pipeline projects, including 45 PPQ/commercialisation projects, and new CDMO orders grew more than 50% in 1H26. The report views this order book as creating strong forward visibility and expects capacity additions—including Shaoxing Phase I in early 2027, accelerating Hangzhou capacity, 1,800L peptide solid-phase capacity in 2026, and late-stage/commercial ADC DS/DP capacity from 2027—to support conversion and margin improvement. The report also identifies favorable mix changes outside CDMO. AIDD customers accounted for more than 7% of 1H26 lab-service revenue, while new molecular types grew more than 60% in bioscience services. HSBC believes these developments strengthen Pharmaron’s ability to capture end-to-end demand from discovery through manufacturing and can help offset foreign-exchange pressure in lab services. Clinical services showed early pricing stabilization, with 2Q gross margin improving 5 percentage points quarter-on-quarter to 12.1%. Automation leverage and rising exposure to complex and late-stage projects are further cited as sources of future margin upside. HSBC values the A-shares with a DCF model using unchanged assumptions: 8.7% WACC, comprising a 4.25% risk-free rate, 4.75% China A-share market-risk premium and 1.26 beta, plus 3.0% terminal growth. It raises 2026-33 EBIT CAGR to 24% from 21% as earnings visibility improves, producing an A-share target price of RMB55.60, up from RMB42.80, implying about 16% upside. For H-shares, it applies an unchanged 0.72x H/A FX-adjusted discount and an unchanged end-2026 RMB/HKD rate of 1.17, resulting in a HKD40.00 target price, up from HKD30.80, implying about 21% upside. HSBC notes that after strong one-month A/H share-price gains of 35%/43%, respectively, versus 2%/6% for CSI300/HSCEI, the shares still trade at 32.8x/19.4x 2027e PE and 1.4x/0.8x 2027 PEG, alongside projected 2026e ROE of 13.3% and visible adjusted net-profit growth of about 20%.

Analysis framework

HSBC starts with the 1H26 operating update and revised company guidance, then links order growth, backlog conversion, capacity additions and business mix to revised earnings forecasts. It compares its forecasts with market consensus, tests 2026 profit sensitivity to revenue growth and margin, and uses DCF valuation for the A-shares with an FX-adjusted H/A discount to derive the H-share target price.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  HSBC discounts Pharmaron’s projected free cash flows using an 8.7% WACC and 3.0% terminal-growth rate to estimate the A-share value, then adjusts for the H/A share discount and FX rate to derive the H-share target.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  End-to-end discovery-to-manufacturing demand capture

  The report connects growth in AIDD and new modalities in discovery and lab services with later-stage CDMO projects and manufacturing conversion, explaining why broader service capabilities can improve revenue visibility and mix.

• Industry AnalysisVolume-price decomposition

  Revenue-growth and net-margin sensitivity analysis

  HSBC shows how different 2026 revenue-growth and net-margin assumptions change projected net profit, illustrating the earnings sensitivity to volume conversion and profitability.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Pharmaron A-shares (300759 CH)

  Primary covered security; CDMO acceleration and stronger earnings visibility underpin the maintained Buy rating.

  Strengths

  Target price RMB55.60; projected c16% upside; 2027e PE of 32.8x, PEG of 1.4x and 2026e ROE of 13.3%.

  Weaknesses

  Lab-service and clinical-service margin assumptions remain relatively conservative versus consensus.

  Comparison

  A-shares rose 35% over the prior month versus a 2% rise in CSI300.

  Risks

  Geopolitical tension, competition-driven margin pressure, regulatory or delivery setbacks, client losses and FX headwinds.

• Pharmaron H-shares (3759 HK)

  Primary covered security; valued from the A-share DCF using an FX-adjusted H/A discount.

  Strengths

  Target price HKD40.00; projected c21% upside; 2027e PE of 19.4x and PEG of 0.8x.

  Weaknesses

  Valuation incorporates an H/A FX-adjusted discount of 0.72x.

  Comparison

  H-shares rose 43% over the prior month versus a 6% rise in HSCEI.

  Risks

  Geopolitical tension, competition-driven margin pressure, regulatory or delivery setbacks, client losses and FX headwinds.

Key data

• 2Q26 revenue growth20.2% y-o-yStronger-than-expected quarterly revenue performance.
• 2Q26 adjusted net-profit growth23.8% y-o-ySupported the earnings upgrade.
• FY26 revenue-growth guidance15-20%Raised from 12-18%.
• CDMO revenue growth42% y-o-y in 2Q26The report’s main earnings catalyst.
• CDMO gross margin26.8%Up 2.7 percentage points quarter-on-quarter in 2Q26.
• 2026-28 net-profit estimate changes+6% / +7% / +8%Driven by backlog conversion and faster CDMO ramp-up.
• A/H target pricesRMB55.60 / HKD40.00Raised from RMB42.80 / HKD30.80.
• 2027e PE32.8x A-shares / 19.4x H-sharesValuation cited after the recent share-price rally.

Impact & implications

HSBC’s central conclusion is that the earnings upgrade is increasingly structural rather than cyclical: a growing CDMO order base, later-stage project progression, complex-molecule mix and added capacity are expected to support growth into 2027. The report considers the revised targets justified despite recent A/H share-price outperformance because it sees continuing earnings visibility and a stronger medium-term mix.

Risks

• Worsening geopolitical tensions and global supply-chain relocation.
• Margin pressure from intense competition.
• Failure to meet regulatory standards, stricter compliance requirements or regulatory delays.
• Project-delivery failures or loss of significant clients.
• Foreign-exchange headwinds.

What to watch

• Recovery in global healthcare financing activity and interest-rate cuts that could increase order backlog.
• China policy support for innovative-drug development.
• Ramp-up of new facilities, including large-molecule capacity.
• Progress in AI implementation and other technological breakthroughs.
• Overseas expansion and M&A announcements.